ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Alectinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has demonstrated superior progression-free survival over crizotinib with both 300 mg twice daily (J-ALEX) or 600 mg twice daily (ALEX, ALESIA) dosing in three pivotal clinical trials. Given the similar med...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Alexandria T M, Ou, Saihong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335304/
https://www.ncbi.nlm.nih.gov/pubmed/37440867
http://dx.doi.org/10.2147/LCTT.S419395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335304/
https://www.ncbi.nlm.nih.gov/pubmed/37440867
http://dx.doi.org/10.2147/LCTT.S419395

Ejemplares similares